share_log

Vivos Therapeutics | 424B1: Prospectus

Vivos Therapeutics | 424B1: Prospectus

Vivos Therapeutics | 424B1：募资说明书
美股sec公告 ·  08/08 17:24
Moomoo AI 已提取核心信息
Vivos Therapeutics, a medical technology company specializing in the treatment of dentofacial abnormalities and sleep apnea, has filed a prospectus with the SEC detailing the resale of shares by a selling stockholder. The selling stockholder, V-CO Investors LLC, affiliated with private equity firm New Seneca Partners, Inc., is offering 169,498 shares of common stock, 3,050,768 shares issuable upon exercise of a Pre-Funded Warrant, and 3,220,266 shares issuable upon exercise of a Common Stock Purchase Warrant. These securities were acquired as part of a private placement that closed on June 10, 2024. Vivos Therapeutics will not receive any proceeds from the sale of the shares, but may receive funds if the warrants are exercised for cash. The shares are listed on The Nasdaq Capital Market under the symbol 'VVOS'. The selling stockholder may sell the shares through various methods including brokerage transactions, block trades, or directly to purchasers. The timing and amount of any sale are at the discretion of the selling stockholder.
Vivos Therapeutics, a medical technology company specializing in the treatment of dentofacial abnormalities and sleep apnea, has filed a prospectus with the SEC detailing the resale of shares by a selling stockholder. The selling stockholder, V-CO Investors LLC, affiliated with private equity firm New Seneca Partners, Inc., is offering 169,498 shares of common stock, 3,050,768 shares issuable upon exercise of a Pre-Funded Warrant, and 3,220,266 shares issuable upon exercise of a Common Stock Purchase Warrant. These securities were acquired as part of a private placement that closed on June 10, 2024. Vivos Therapeutics will not receive any proceeds from the sale of the shares, but may receive funds if the warrants are exercised for cash. The shares are listed on The Nasdaq Capital Market under the symbol 'VVOS'. The selling stockholder may sell the shares through various methods including brokerage transactions, block trades, or directly to purchasers. The timing and amount of any sale are at the discretion of the selling stockholder.
医疗技术公司Vivos Therapeutics专注于治疗牙面畸形和睡眠呼吸暂停，已向美国证券交易委员会提交了一份招股说明书，详细说明了售股股东的股票转售。售股股东V-CO Investors LLC与私募股权公司New Seneca Partners，Inc有关联，提供169,498股普通股，3,050,768股可在行使预先拟定认股权证时发行，以及3,220,266股可在行使普通股认股权证时发行。这些证券是作为2024年6月10日结束的定向增发的一部分获得的。Vivos Therapeutics不会从股票出售中获得任何收益，但如果认股权证以现金行使，则可以获得资金。这些股票在纳斯达克股票市场以“VVOS”标的上市。售出股票的售股股东可以通过各种方式进行售出，包括券商交易，大宗交易或直接出售给购买者。任何售出股数和时间均由售股股东自行决定。
医疗技术公司Vivos Therapeutics专注于治疗牙面畸形和睡眠呼吸暂停，已向美国证券交易委员会提交了一份招股说明书，详细说明了售股股东的股票转售。售股股东V-CO Investors LLC与私募股权公司New Seneca Partners，Inc有关联，提供169,498股普通股，3,050,768股可在行使预先拟定认股权证时发行，以及3,220,266股可在行使普通股认股权证时发行。这些证券是作为2024年6月10日结束的定向增发的一部分获得的。Vivos Therapeutics不会从股票出售中获得任何收益，但如果认股权证以现金行使，则可以获得资金。这些股票在纳斯达克股票市场以“VVOS”标的上市。售出股票的售股股东可以通过各种方式进行售出，包括券商交易，大宗交易或直接出售给购买者。任何售出股数和时间均由售股股东自行决定。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息